Skip to main content
. 2019 Oct 14;6(6):e631. doi: 10.1212/NXI.0000000000000631

Figure 1. Subjects with amyotrophic lateral sclerosis (ALS) exhibit increased levels of interleukin 6 (IL6) in serum and CSF.

Figure 1

(A) Serum IL6 is significantly elevated in subjects with ALS compared with healthy controls (HCs) (p = 0.040, Cohen's D = 0.62) but not to disease controls (DCs) (p = 0.94) controls. (B) CSF IL6 is elevated in subjects with ALS compared with both HCs (p < 0.001, D = 0.61) and DCs (p = 0.021, D = 0.28). (C) Neither serum (ALS vs HC p = 0.30, vs DC p = 0.21) nor (D) CSF (ALS vs HC p = 0.32, vs DC p = 0.85) sIL6R varies with disease status. (E) Serum (ALS vs HC p = 0.28, vs DC p = 0.09) and (F) CSF sgp130 (ALS vs HC p = 0.18, vs DC p = 0.07) do not vary with disease status. (A) = p < 0.05, b = p < 0.001. For sgp130 and CSF IL6, all were planned comparisons where significance was determined by the Student t test. For serum IL6, significance was determined with generalized linear models, followed by Fisher protected least significant difference for planned individual comparisons of ALS vs HCs and ALS vs DCs; graphed values for IL6 are least squared means.